Andrew Cuthbertson
Chief Scientific Officer and R&D Director
global operations of Research and Development
CSL Behring Bio therapies for Life
Australia
Biography
After completing medical training at the University of Melbourne and Ph.D. in Immunology at the Walter and Eliza Hall Institute in Australia, Dr. Cuthbertson spent five years doing molecular biology research as a staff member at the Howard Florey Institute in Melbourne and the National Institutes of Health in the United States. He then spent seven years at Genentech, Inc. in San Francisco working on anti–VEGF therapy for age related macular degeneration
Research Interest
With a keen interest in biopharmaceutical drug development, Dr. Cuthbertson joined the company in 1997 as Research Director. He was promoted to R&D Director in March 2000. In his current role as R&D Director and Chief Scientific Officer, Dr. Cuthbertson manages an internal R&D budget of over $350m, and a global R&D organisation of 800 scientists. He is responsible for crafting the global R&D strategy for CSL.
